1. Richeldi L et al. N Engl J Med 2014;370:2071-82.
2. Flaherty KR et al. N Engl J Med 2019;381:1718-27.

The INBUILD and INPULSIS trials were funded by Boehringer Ingelheim. Editorial and formatting assistance, supported financially by Boehringer Ingelheim, was provided by Julie Fleming and Wendy Morris of FleishmanHillard Fishburn, London, UK during preparation of this poster. The authors were fully responsible for all content and editorial decisions, were involved at all stages of poster development and have approved the final version. Boehringer Ingelheim was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. The authors received no direct compensation related to the development of this poster. Fernando J Martinez reports being on Steering Committees for ILD studies sponsored by Bayer, Biogen, Gilead, Nitto, Patara/Respivant, ProMedior, ProMetic, and Veracyte; a member of the Data and Safety Monitoring Board for studies supported by Biogen, Boehringer Ingelheim, and Genentech; and a consultant for Boehringer Ingelheim, Genentech, and Zambon. Vincent Cottin reports research grants, personal fees, and non-financial support from Boehringer Ingelheim and Roche; personal fees from Bayer/Merck Sharp & Dohme, Celgene, Galapagos, Galecto, Gilead, Novartis, Promedior, and Sanofi; and personal fees and non-financial support from Actelion.